摘要
目的 探讨血管免疫母细胞性T细胞淋巴瘤患者的EB病毒感染情况及其临床病理学意义.方法 回顾性分析2008年1月至2011年12月经常规外检及会诊确诊的血管免疫母细胞性T细胞淋巴瘤62例,进行常规形态学和免疫学表型分析,采用原位杂交方法检测EB病毒编码小RNA（EBV-EBER）的表达情况,并随访患者.结果 62例血管免疫母细胞性T细胞淋巴瘤患者中,EBV-EBER阳性者26例（42％）.EBV-EBER表达与患者年龄大于60岁以及治疗反应密切相关（P=0.025、0.049）,而与患者的总体生存时间、临床B症状及Ann Arbor分期无关（均P＞0.05）.结论 血管免疫母细胞性T细胞淋巴瘤患者EB病毒感染不影响总体生存时间,但影响患者对治疗的反应.
Objective To investigate the EB virus （EBV） infection and its clinical significance in angioimmunoblastic T-cell lymphoma（AITCL）.Methods 62 patients diagnosed as AITCL between 2008 Jan and 2011 Dec were retrospective analyzed.All cases were re-confirmed and classified with the histology and immunology according to 2008 WHO Classification.In situ hybridization of EBV encoded RNA （EBV-EBER） was performed.Clinical characteristics and follow-up data of patients were collected.Results 42 % （26/62） AITCL cases were EBER-positive.EBV infection was found to be significant correlation with age over 60 years and poor response to therapy （P =0.025,P =0.049,respectively）.However,EBV infection had no relationship with the overall survival,the presence of B symptom and the Ann Arbor stage.Conclusion In AITCL,EBV infection seems not to be associated with the overall survival,B symptom and Ann Arbor stage,but it may have impacts on theraputic response.
出处
《白血病．淋巴瘤》
CAS
2014年第2期96-99,共4页
Journal of Leukemia & Lymphoma
